Page last updated: 2024-11-05

troglitazone and Focal Segmental Glomerulosclerosis

troglitazone has been researched along with Focal Segmental Glomerulosclerosis in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ma, LJ1
Marcantoni, C1
Linton, MF1
Fazio, S1
Fogo, AB1

Other Studies

1 other study available for troglitazone and Focal Segmental Glomerulosclerosis

ArticleYear
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
    Kidney international, 2001, Volume: 59, Issue:5

    Topics: Animals; Antihypertensive Agents; Base Sequence; Chromans; Disease Models, Animal; DNA Primers; Glom

2001